The Emerging Issue of Cardiac Dysfunction Induced by Antineoplastic Angiogenesis Inhibitors
- 1 May 2013
- journal article
- review article
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
- Vol. 15 (5) , 482-489
Abstract
Left ventricular dysfunction from anticancer drugs has emerged as a relevant problem in the clinical and scientific communities. Anthracycline toxicity has always been the most relevant, but with the increasing use of biological targeted therapies in treatment protocols, with an increasing number of cancer survivors, new toxicities have been increasing in more recent years. Cardiomyopathy after ErbB2 inhibitors has been intensively studied. Another important class of biological anticancer drugs are vascular endothelial growth factor (VEGF) inhibitors. VEGF signalling is crucial for vascular growth, but it also has a major impact on myocardial function. Also, it is important to note that such angiogenesis inhibitors are multitargeted in most cases, and can produce a broad spectrum of cardiovascular side effects. Here we review the mechanisms and pathophysiology of the most significant cardiotoxic effects of antiangiogenic drugs, and particular attention is drawn to LV dysfunction, discussing the assessment and management on the basis of the most recent cardio-oncological findings and heart failure guidelines.Keywords
This publication has 56 references indexed in Scilit:
- ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012European Journal of Heart Failure, 2012
- Cardiac angiogenic imbalance leads to peripartum cardiomyopathyNature, 2012
- Eplerenone in Patients with Systolic Heart Failure and Mild SymptomsNew England Journal of Medicine, 2011
- Initial Assessment, Surveillance, and Management of Blood Pressure in Patients Receiving Vascular Endothelial Growth Factor Signaling Pathway InhibitorsJNCI: Journal of the National Cancer Institute, 2010
- The transcriptional coactivator PGC-1α mediates exercise-induced angiogenesis in skeletal muscleProceedings of the National Academy of Sciences of the United States of America, 2009
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast CancerNew England Journal of Medicine, 2007
- Cardiotoxicity associated with tyrosine kinase inhibitor sunitinibThe Lancet, 2007
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Tumor Angiogenesis: Therapeutic ImplicationsNew England Journal of Medicine, 1971